Seroflo: Advanced Dual-Action Asthma and COPD Control
Seroflo
| Product dosage: 250mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $110.00 | $110.00 (0%) | 🛒 Add to cart |
| 2 | $94.50 | $220.00 $189.00 (14%) | 🛒 Add to cart |
| 3 | $89.00 | $330.00 $267.00 (19%) | 🛒 Add to cart |
| 4 | $86.25 | $440.00 $345.00 (22%) | 🛒 Add to cart |
| 5 | $84.80 | $550.00 $424.00 (23%) | 🛒 Add to cart |
| 6 | $83.67 | $660.00 $502.00 (24%) | 🛒 Add to cart |
| 7 | $83.00 | $770.00 $581.00 (25%) | 🛒 Add to cart |
| 8 | $82.38
Best per inhaler | $880.00 $659.00 (25%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Seroflo represents a significant advancement in the management of obstructive airway diseases, combining two established therapeutic agents into a single, convenient inhaler. This fixed-dose combination therapy integrates an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) to address both the underlying inflammation and bronchoconstriction characteristic of asthma and chronic obstructive pulmonary disease (COPD). Its development is grounded in the GINA (Global Initiative for Asthma) and GOLD (Global Initiative for Chronic Obstructive Lung Disease) strategy documents, which recommend such combinations for patients requiring Step 3 or 4 therapy or those with frequent exacerbations. By simplifying treatment regimens, Seroflo enhances adherence and provides a robust approach to achieving and maintaining disease control, improving long-term patient outcomes and quality of life.
Features
- Fixed-dose combination of Fluticasone Propionate (an inhaled corticosteroid) and Salmeterol (a long-acting beta2-agonist).
- Available in multiple strength configurations (e.g., Fluticasone 100/250/500 mcg + Salmeterol 25/50 mcg) to allow for individualized treatment escalation and de-escalation.
- Delivered via a pressurized metered-dose inhaler (pMDI) with a dose counter for accurate administration tracking.
- Engineered with hydrofluoroalkane (HFA) as the propellant, which is chlorofluorocarbon (CFC)-free and environmentally conscious.
- Designed for twice-daily (BID) maintenance use, providing 24-hour coverage with two doses.
- The mechanism offers local action within the lungs, minimizing systemic exposure and potential side effects.
Benefits
- Superior Symptom Control: Effectively reduces the frequency and severity of daytime and nighttime asthma symptoms and COPD exacerbations.
- Dual-Action Efficacy: Targets both airway inflammation (via the corticosteroid) and bronchospasm (via the bronchodilator) for comprehensive disease management.
- Improved Lung Function: Demonstrated to significantly increase Forced Expiratory Volume in one second (FEV1) and peak expiratory flow (PEF) measurements.
- Enhanced Treatment Adherence: A single inhaler regimen is simpler than using two separate devices, reducing the chance of patient error and missed doses.
- Reduced Reliance on Rescue Medication: Provides consistent background control, decreasing the need for short-acting beta2-agonist (SABA) use.
- Prevention of Future Risk: Helps prevent asthma attacks and COPD flare-ups, protecting lung function over the long term and reducing hospitalization rates.
Common use
Seroflo is indicated for the regular maintenance treatment of asthma in patients where a combination product is appropriate, typically those not adequately controlled on inhaled corticosteroids and “as-needed” short-acting bronchodilators, or those whose disease severity clearly warrants initiation of treatment with two maintenance therapies. It is also indicated for the symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. It is crucial to note that Seroflo is not indicated for the relief of acute bronchospasm and should not be used as a rescue medication.
Dosage and direction
The dosage of Seroflo must be individualized based on disease severity and prior therapy. The lowest effective dose should always be used.
- For Asthma: The usual recommended dose for adults and adolescents (12 years and older) is two inhalations twice daily (morning and evening, approximately 12 hours apart). The strength (e.g., 100/25, 250/25, or 500/50) is determined by the physician.
- For COPD: The usual recommended dose is one inhalation of Seroflo 250/25 or 500/50 twice daily.
- Administration: Shake the inhaler well before each inhalation. Breathe out fully, place the mouthpiece between your lips, and form a tight seal. Start to breathe in slowly and deeply through your mouth, and simultaneously press down firmly on the canister to release the medication. Continue to breathe in deeply. Hold your breath for about 10 seconds, or for as long as is comfortable, then breathe out slowly. Wait at least 30-60 seconds before shaking the inhaler and taking the second puff, if prescribed.
- Important: Rinse your mouth with water and spit it out after each dose to help prevent oral candidiasis (thrush) and hoarseness.
Precautions
- Seroflo is not a bronchodilator and should not be used to treat acute symptoms. Patients must have a separate, fast-acting inhaler (e.g., salbutamol) for acute relief.
- Paradoxical bronchospasm (immediate wheezing and shortness of breath after dosing) can occur. If this happens, treatment should be discontinued immediately and alternative therapy instituted.
- Patients should be advised to seek medical advice if their short-acting inhaler becomes less effective or they need to use it more often, as this is a sign of deteriorating asthma control.
- Systemic effects of corticosteroids may occur, particularly at high doses and over prolonged periods. These may include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataracts, and glaucoma.
- A reduction in bone mineral density has been observed with long-term administration of products containing ICS. Patients with major risk factors for decreased bone mineral content should be monitored.
- Be cautious in patients with tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.
Contraindications
Seroflo is contraindicated in patients with a known hypersensitivity to Fluticasone Propionate, Salmeterol, or any of the excipients (e.g., lactose). Its use to treat acute asthma attacks or status asthmaticus is also contraindicated. Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required is not appropriate with this medication.
Possible side effect
Like all medicines, Seroflo can cause side effects, although not everybody gets them.
Very common (≥1/10):
- Headache
Common (≥1/100 to <1/10):
- Oral candidiasis (thrush)
- Hoarseness or dysphonia
- Throat irritation
- Palpitations
- Tremor
- Tachycardia
- Muscle cramps
- Nausea and vomiting
- Cough
Uncommon (≥1/1,000 to <1/100):
- Skin reactions (rash, urticaria, pruritus)
- Anxiety, sleep disturbances, restlessness
- Hyperglycemia (especially in diabetics)
- Cataracts, glaucoma
- Dyspepsia
Rare (≥1/10,000 to <1/1,000):
- Anaphylactic reactions
- Angioedema
- Psychiatric effects (e.g., depression, behavioral changes)
- Atrial fibrillation, other cardiac arrhythmias
- Paradoxical bronchospasm
Very rare (<1/10,000):
- Systemic eosinophilic conditions
- Adrenal suppression (with high doses)
Drug interaction
Concomitant use of Seroflo with the following medications requires caution and possibly dose adjustment:
- Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir, Clarithromycin): Co-administration may significantly increase systemic exposure to Salmeterol, increasing the risk of cardiovascular side effects (prolonged QTc interval, palpitations, tachycardia). Avoid concomitant use unless the benefit outweighs the increased risk.
- Beta-blockers (e.g., Propranolol): May antagonize the bronchodilatory effect of Salmeterol and produce severe bronchospasm in asthmatic patients. Use cardioselective beta-blockers with caution if necessary.
- Diuretics, Xanthine derivatives, Steroids: May potentiate the hypokalemic effect of beta2-agonists like Salmeterol.
- Other Beta-adrenergic Drugs: Concomitant use with other sympathomimetic agents may potentiate the sympathetic effects of Salmeterol.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. The dose should not be doubled to make up for a forgotten dose. Patients should be instructed to never take more than the prescribed number of inhalations in a given time period.
Overdose
Overdose may manifest as exaggeration of the known pharmacologic effects of its components, primarily Salmeterol.
- Salmeterol Overdose: Signs and symptoms may include tachycardia, arrhythmias, tremor, headache, muscle cramps, hyperglycemia, hypokalemia, and hypotension.
- Fluticasone Overdose: Acute overdose is unlikely, but chronic overdosage may lead to systemic corticosteroid effects such as hypercorticism and adrenal suppression.
- Management: Treatment is supportive and symptomatic. Cardiac monitoring is recommended. Hypokalemia should be corrected. There is no known specific antidote. Since Salmeterol is long-acting, monitoring should continue for at least 12-16 hours.
Storage
Store at room temperature (15°C to 30°C). Do not puncture or incinerate the canister, even when it is empty. Keep away from direct sunlight, heat, and open flame. The canister is pressurized. The inhaler should be stored with the mouthpiece down. Keep out of the sight and reach of children. Do not use the inhaler after the expiration date printed on the carton and canister. The dose counter indicates the number of doses remaining.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided is based on the typical properties of the drug and may not cover all possible uses, directions, precautions, interactions, or adverse effects.
Reviews
- Clinical Evidence: “The combination of fluticasone propionate and salmeterol in a single inhaler has been extensively studied in large-scale clinical trials (e.g., the GOLDEN studies for COPD). Data consistently shows superior efficacy in improving lung function (FEV1) and reducing exacerbation rates compared to monotherapy with either component alone, with a well-characterized safety profile.” – Pulmonology Research Review
- Practitioner Perspective: “In my practice, Seroflo has been a cornerstone for managing moderate-to-severe asthma. The convenience of a combination inhaler significantly improves adherence in my patients, which directly translates to better symptom control and fewer emergency department visits. Monitoring for oral thrush and ensuring proper inhaler technique are key.” – Dr. A. Sharma, Respiratory Specialist.
- Patient Feedback: “Since switching to Seroflo, my morning wheezing has completely disappeared. I only need my rescue inhaler once or twice a month now, compared to almost daily before. Remembering to rinse my mouth is a small price to pay for being able to breathe properly and play with my grandchildren.” – Verified Patient, 68.